These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32311799)

  • 1. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Al-Batran SE; Moorahrend E; Maintz C; Goetze TO; Hempel D; Thuss-Patience P; Gaillard VE; Hegewisch-Becker S
    Oncologist; 2020 Aug; 25(8):e1181-e1187. PubMed ID: 32311799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
    Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
    Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
    Qin S; Ji J; Xu RH; Wang W; Tang Y; Bi F; Li J; Wang K; Xu JM; Fan Q; Su W; Shen L
    Oncologist; 2021 Sep; 26(9):e1567-e1580. PubMed ID: 34003545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
    Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
    Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
    Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
    Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
    Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
    Grieb BC; Agarwal R
    Curr Treat Options Oncol; 2021 Aug; 22(10):88. PubMed ID: 34424404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
    Sawaki A; Ohashi Y; Omuro Y; Satoh T; Hamamoto Y; Boku N; Miyata Y; Takiuchi H; Yamaguchi K; Sasaki Y; Nishina T; Satoh A; Baba E; Tamura T; Abe T; Hatake K; Ohtsu A
    Gastric Cancer; 2012 Jul; 15(3):313-22. PubMed ID: 22179434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
    Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
    Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY
    Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study.
    Abali H; Yalcin S; Onal HC; Dane F; Oksuzoglu B; Ozdemir N; Mertsoylu H; Artac M; Camci C; Karabulut B; Basal FB; Budakoglu B; Sendur MAN; Goktas B; Ozdener F; Baygul A
    Am J Clin Oncol; 2021 Jul; 44(7):301-307. PubMed ID: 33979100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
    Aktürk Esen S; Ergun Y; Erol C; Arikan R; Er MM; Atci MM; Topçu A; Uçar G; Akagündüz B; Aykan MB; Özen M; Baytemur NK; Özçelik M; Şahin E; Güven D; Menekşe S; Ak N; Teker F; Kut E; Şakalar T; Alan Ö; Kaçan T; Turhal NS; Kiliçkap S; Türker S; Şendur MAN; Köstek O; Karaağaç M; Sakin A; Türk HM; Çağlayan D; Cihan Ş; Açikgöz Y; Uncu D
    Bosn J Basic Med Sci; 2022 Sep; 22(5):818-825. PubMed ID: 35460397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
    Shah MA; Xu RH; Bang YJ; Hoff PM; Liu T; Herráez-Baranda LA; Xia F; Garg A; Shing M; Tabernero J
    J Clin Oncol; 2017 Aug; 35(22):2558-2567. PubMed ID: 28574779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.
    Hackshaw MD; Bui CL; Ladner A; Tu N; Islam Z; Ritchey ME; Salas M
    Cancer Treat Res Commun; 2020; 24():100189. PubMed ID: 32673845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
    Yamaguchi K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Shimoyama T; Lee KW; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Shitara K
    J Clin Oncol; 2023 Feb; 41(4):816-825. PubMed ID: 36379002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
    Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
    Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
    Grávalos C; Gómez-Martín C; Rivera F; Alés I; Queralt B; Márquez A; Jiménez U; Alonso V; García-Carbonero R; Sastre J; Colomer R; Cortés-Funes H; Jimeno A
    Clin Transl Oncol; 2011 Mar; 13(3):179-84. PubMed ID: 21421462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.